[go: up one dir, main page]

WO2000000183A3 - Antioxidant, cytostatic and sustained energy composition which ameliorates the metabolic utilization of glucose comprising acetyl-l-carnitine and a catechin - Google Patents

Antioxidant, cytostatic and sustained energy composition which ameliorates the metabolic utilization of glucose comprising acetyl-l-carnitine and a catechin Download PDF

Info

Publication number
WO2000000183A3
WO2000000183A3 PCT/IT1999/000176 IT9900176W WO0000183A3 WO 2000000183 A3 WO2000000183 A3 WO 2000000183A3 IT 9900176 W IT9900176 W IT 9900176W WO 0000183 A3 WO0000183 A3 WO 0000183A3
Authority
WO
WIPO (PCT)
Prior art keywords
carnitine
acetyl
catechin
ameliorates
cytostatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT1999/000176
Other languages
French (fr)
Other versions
WO2000000183A2 (en
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau HealthScience SpA
Original Assignee
Sigma Tau HealthScience SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau HealthScience SpA filed Critical Sigma Tau HealthScience SpA
Priority to AU43911/99A priority Critical patent/AU4391199A/en
Publication of WO2000000183A2 publication Critical patent/WO2000000183A2/en
Publication of WO2000000183A3 publication Critical patent/WO2000000183A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

A composition for the prevention and/or therapeutic treatment of various alterations and pathological states induced by free radicals, that may take the form of a dietary supplement, dietetic support or of an actual medicine, is disclosed which comprises as characterizing active ingredients acetyl L-carnitine and at least one of the catechins (e.g. epigallocatechin gallate) that can be extracted from the green tea.
PCT/IT1999/000176 1998-06-30 1999-06-17 Antioxidant, cytostatic and sustained energy composition which ameliorates the metabolic utilization of glucose comprising acetyl-l-carnitine and a catechin Ceased WO2000000183A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU43911/99A AU4391199A (en) 1998-06-30 1999-06-17 Antioxidant, cytostatic and sustained energy composition which ameliorates the metabolic utilization of glucose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM98A000433 1998-06-30
IT98RM000433A IT1299197B1 (en) 1998-06-30 1998-06-30 COMPOSITION WITH ANTI-OXIDANT, ANTIPOLIFERATIVE, ENERGETIC ACTIVITY AND SUITABLE TO IMPROVE THE METABOLIC USE OF GLUCOSE.

Publications (2)

Publication Number Publication Date
WO2000000183A2 WO2000000183A2 (en) 2000-01-06
WO2000000183A3 true WO2000000183A3 (en) 2000-06-29

Family

ID=11406017

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1999/000176 Ceased WO2000000183A2 (en) 1998-06-30 1999-06-17 Antioxidant, cytostatic and sustained energy composition which ameliorates the metabolic utilization of glucose comprising acetyl-l-carnitine and a catechin

Country Status (5)

Country Link
AR (1) AR019737A4 (en)
AU (1) AU4391199A (en)
IT (1) IT1299197B1 (en)
TN (1) TNSN99138A1 (en)
WO (1) WO2000000183A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1316997B1 (en) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF VASCULOPATHIES, WHICH INCLUDES PROPIONYL L-CARNITINE AND COENZYME Q10.
IT1317035B1 (en) * 2000-05-30 2003-05-26 Sigma Tau Healthscience Spa SUPPLEMENT WITH ANTIOXIDANT ACTIVITY INCLUDING AN ALKANOILCARNITINE AND AN ASSOCIATION OF POLYPHENOLS EXTRACTED FROM
IT1317036B1 (en) * 2000-05-30 2003-05-26 Sigma Tau Healthscience Spa SUPPLEMENT TO ANTIOXIDANT ACTIVITY INCLUDING AN ALKANOILCARNITINE AND AN ASSOCIATION OF POLYPHENOLS EXTRACTED FROM PLANTS
US6923960B2 (en) 2001-10-03 2005-08-02 Vsl Pharmaceuticals Inc. Antioxidant combination composition and use thereof
US20050271603A1 (en) * 2002-07-26 2005-12-08 Stephanie Krammer Compositions comprising lactoferrin
CA2531056A1 (en) * 2002-10-11 2004-04-22 Creagri, Inc. Therapeutic combination of carnitine and antioxidant polyphenols
JP2005089384A (en) * 2003-09-18 2005-04-07 Kao Corp Endurance improver
US7205011B2 (en) 2003-11-14 2007-04-17 Board Of Regents, Acting For And On Behalf Of, University Of Arizona Anti-inflammatory activity of a specific turmeric extract
US20070286925A1 (en) * 2006-06-08 2007-12-13 The Procter & Gamble Company Composition for improving eye health
CA2654303C (en) * 2006-06-08 2016-07-26 The Iams Company Use of at least one polyphenol for promoting eye health
CA2885388C (en) 2012-10-04 2018-01-02 Abbott Laboratories Methods for enhancing the effect of egcg on mitigating skeletal muscle loss

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2388556A1 (en) * 1977-04-29 1978-11-24 Sigma Tau Ind Farmaceuti THERAPEUTIC APPLICATION OF ACETYL-CARNITINE-D, 1 AND OTHER ACYLIC DERIVATIVES OF CARNITINE-D, 1
WO1997002041A1 (en) * 1995-07-03 1997-01-23 Crandall Wilson T Transdermal and oral treatment of androgenic alopecia
EP0773020A2 (en) * 1995-10-17 1997-05-14 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Pharmaceutical compositions containing L-carnitine or derivatives thereof in combination with resveratrol or derivatives thereof, for the prophylaxis and treatment of cardiovascular disorders, peripheral vascular diseases and peripheral diabetic neuropathy
US5667791A (en) * 1996-05-31 1997-09-16 Thione International, Inc. X-ray induced skin damage protective composition
WO1998033494A1 (en) * 1997-02-04 1998-08-06 Kosbab John V Compositions and methods for prevention and treatment of vascular degenerative diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2388556A1 (en) * 1977-04-29 1978-11-24 Sigma Tau Ind Farmaceuti THERAPEUTIC APPLICATION OF ACETYL-CARNITINE-D, 1 AND OTHER ACYLIC DERIVATIVES OF CARNITINE-D, 1
WO1997002041A1 (en) * 1995-07-03 1997-01-23 Crandall Wilson T Transdermal and oral treatment of androgenic alopecia
EP0773020A2 (en) * 1995-10-17 1997-05-14 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Pharmaceutical compositions containing L-carnitine or derivatives thereof in combination with resveratrol or derivatives thereof, for the prophylaxis and treatment of cardiovascular disorders, peripheral vascular diseases and peripheral diabetic neuropathy
US5667791A (en) * 1996-05-31 1997-09-16 Thione International, Inc. X-ray induced skin damage protective composition
WO1998033494A1 (en) * 1997-02-04 1998-08-06 Kosbab John V Compositions and methods for prevention and treatment of vascular degenerative diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOTTA ET AL: "Effects of Propionyl-L-Carnitine and Insulin on the Electroretinogram, Nerve Conduction and Nerve Blood Flow in Rats with Streptozotocin-Induced Diabetes", PFLUEGERS ARCHIV EUROPEAN JOURNAL OF PHYSIOLOGY, vol. 431, no. 4, 1996, pages 564 - 570, XP000874774 *
MATSUOKA ET AL: "Ameliorative Effects of Tea Catechins on Active Oxygen-Related Nerve Cell Injuries", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 274, no. 2, 1995, pages 602 - 608, XP000878596 *
SCHOEMAKER: "Pharmacological Treatment of Diabetic Peripheral Neuropathy: Challenges and Possibilities", BRITISH JOURNAL OF CLINICAL PRACTICE, vol. 48, no. 2, 1994, pages 91 - 96, XP000878610 *
SOLIMAN ET AL: "In Vitro Attenuation of Nitric Oxide Production in C6 Astrocyte Cell Culture by Various Dietary Compounds", PROC. SOC. EXP. BIOL. MED., vol. 218, no. 4, 1998, pages 390 - 397, XP000867853 *

Also Published As

Publication number Publication date
IT1299197B1 (en) 2000-02-29
ITRM980433A1 (en) 1999-12-30
AR019737A4 (en) 2002-03-13
WO2000000183A2 (en) 2000-01-06
TNSN99138A1 (en) 2005-11-10
AU4391199A (en) 2000-01-17
ITRM980433A0 (en) 1998-06-30

Similar Documents

Publication Publication Date Title
WO2000011968A8 (en) ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND α-LIPOIC ACID
WO1999066913A3 (en) Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-l-carnitine and genistein
WO2003057201A3 (en) A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
WO2000000183A3 (en) Antioxidant, cytostatic and sustained energy composition which ameliorates the metabolic utilization of glucose comprising acetyl-l-carnitine and a catechin
NO20021640L (en) Composition for the prevention and / or treatment of circulatory diseases comprising derivatives of L-carnitine and extracts of Gingo biloba
CA2253130A1 (en) A medicament for treating obesity and improving lipid metabolism
EP1192949A4 (en) ACIDS WITH CHYMASEINHIBITORS AS EFFECTIVE MEANS FOR THE PREVENTION OR TREATMENT OF FIBROSIS
CA2335015A1 (en) Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug
WO2000007581A3 (en) Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid
CA2350220A1 (en) Antioxidant composition comprising propionyl l-carnitine and a flavonoid against thrombosis and atherosclerosis
NO20022288L (en) Composition for the prevention and / or treatment of disorders caused by abnormal lipid metabolism, including propionyl L-carnitine and chitosan
WO2001007039A3 (en) L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
AU2904700A (en) Pharmaceutical composition effective against pathological conditions caused by bacteria, viruses, fungi, yeasts and protozoa
JP2001055571A5 (en) Antioxidant compositions and foods
EP0737476A3 (en) A pharmaceutical preparation containing a 3-(2H)-furanone derivative for prevention and/or treatment of cataracts
WO2011091299A1 (en) Composition for perinatal and neonatal stroke
WO2001003683A3 (en) Cardioactive composition comprising l-carnitine and its derivatives and crataegus extracts
WO2002083660A1 (en) Remedies
WO2003057224A1 (en) Apoptosis inductor
WO2002096218A3 (en) Combination of lipoic acids, carnitines, and creatines in food and pharmaceuticals
WO2000003699A3 (en) Drugs containing phosphoric acid derivatives as active ingredient and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase